Trial Profile
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Dynamic Hypermutation Status
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ARETHUSA
- 26 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 26 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Jun 2024.
- 26 Sep 2023 Status changed from recruiting to active, no longer recruiting.